Safety of an intravenous formulation of lamotrigine

Seizure

Volumn 23, Issue 5, 2014, Pages 390-392

  Conway, Jeannine M ^a   Birnbaum, Angela K ^a   Leppik, Ilo E ^a,b,c   Pennell, Page B ^d   White, James R ^c   Rarick, John O ^a   Remmel, Rory P ^b  

^a Exp and Clinical Pharmacology   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MINCEP Epilepsy Care   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cyclodextrin; Epilepsy; Intravenous; Lamotrigine; Safety

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; LAMOTRIGINE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTICONVULSIVE AGENT; BETA CYCLODEXTRIN DERIVATIVE; TRIAZINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; AGED; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BETA-CYCLODEXTRINS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIAZINES; YOUNG ADULT;

EID: 84899633987     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2014.01.019     Document Type: Article

References (12)

1. J.E. Ahn, J.C. Cloyd, R.C. Brundage, S.E. Marino, J.M. Conway, and R.E. Ramsay et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy Neurology 71 2008 38 43
2. A.M. Clark, R.L. Kriel, I.E. Leppik, J.R. White, T.R. Henry, and R.C. Brundage et al. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate Epilepsia 54 2013 1106 1111
3. S.E. Marino, A.K. Birnbaum, I.E. Leppik, J.M. Conway, L.C. Musib, and R.C. Brundage et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex Clin Pharmacol Ther 9 2012 483 488
4. B. Punyawudho, J.C. Cloyd, I.E. Leppik, R.E. Ramsay, S.E. Marino, and P.B. Pennell et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model Clin Pharmacokinet 48 2009 313 320
5. R.P. Remmel, J. Conway, I.E. Leppik, J.L. Beattie, J.R. White, and R.E. Ramsay et al. Valproic acid pharmacokinetics and bioavailability determined by a stable isotope technique Epilepsia 46 2005 183
6. W.C. Yuen, and A.W. Peck Lamotrigine pharmacokinetics: oral and i.v. infusion in man Br J Clin Pharmacol 26 1988 242P
7. T. Loftsson, and M.E. Brewster Cyclodextrins as functional excipients: methods to enhance complexation efficiency J Pharm Sci 101 2012 3019 3032
8. K.R. Parmar, K.A. Patel, S.R. Shah, and N.R. Sheth Inclusion complexes of lamotrigine and hydroxy propyl-β cyclodextrin: solid state characterization and dissolution studies J Incl Phenom Macrocycl Chem 65 2009 263 268
9. V.R. Shinde, M.R. Shelake, S.S. Shetty, A.B. Chavan-Patil, Y.V. Pore, and S.G. Late Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique J Pharm Pharmacol 60 2008 1121 1129
10. R.P. Remmel, and M.W. Sinz A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In vitro and in vivo studies Drug Metab Dispos 19 1991 630 636
11. A.H. Guberman, F.M. Besag, M.J. Brodie, J.M. Dooley, M.S. Duchowny, and J.M. Pellock et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children Epilepsia 40 1999 985 991
12. J.M. Conway, J.R. White, A.K. Birnbaum, R.E. Ramsay, P.B. Pennell, and J.O. Rarick et al. Safety of an IV formulation of carbamazepine Epilepsy Res 84 2009 242 244